To learn which 5-HT pathway proteins are required for human BTIC survival, the activity of those selective 5-HT antagonists that were commercially available was evaluated in up to 10 human breast tumor cell lines modeling all breast cancer subtypes using alamarBlue cell viability and quantitative sphere-forming assays. Here, HTR5A is linked to breast carcinoma.